Annovis Bio, Inc.

We are a late-stage clinical drug platform company addressing neurodegeneration, such as Alzheimer’s disease ( AD ) and Parkinson’s disease ( PD ). We are developing our lead product candidate, buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. In several studies, buntanetap was observed to inhibit the synthesis of neurotoxic proteins APP/A ( APP ), tau/phospho-tau ( tau ), -Synuclein ( SYN ) and TDP43 that are some of the main causes of neurodegeneration. High levels of neurotoxic proteins lead to reduced axonal transport, which is responsible for communication between and within nerve cells. When that communication is compromised, the immune system is activated and attacks the nerve cells, eventually killing them. We have observed in our completed clinical studies in AD and PD patients and pre-clinical studies in mice and rats that buntanetap lowered neurotoxic protein levels leading to improved axonal transport, reduced inflammation, lower nerve cell death and improved affected function. Currently we are conducting two clinical studies a pivotal Phase 3 study in early AD ( Phase 3 AD Trial ) (NCT06709014) and an open-label extension ( OLE ) study in PD (NCT07284784), and we plan for a third study in Parkinson’s disease dementia ( PDD ). In February of 2025, we initiated the FDA-cleared pivotal Phase 3 AD Trial: a randomized, double-blind, placebo-controlled, multicenter Phase 3 study in 760 early AD patients.